Background:

ML 145 is a selective GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM, but not for the related GPR55 orphan receptor[1]. GPR35 is expressed by various cells of the immune system and it may has potential as a therapeutic target in inflammatory disease[2].

参考文献:
[1]. Heynen-Genel S, et al. Selective GPR35 Antagonists - Probes 1 & 2. National Center for Biotechnology Information (US); 2010-2010 Feb 28.
[2]. Binti Mohd Amir NAS, et al. Evidence for the Existence of a CXCL17 Receptor Distinct from GPR35. J Immunol. 2018 Jul 15;201(2):714-724.